Andrea L. Merz

Pharmacokinetics of combined doxorubicin and paclitaxel in mice

Daniel L. Gustafson, Andrea L. Merz, Michael E. Long · Cancer Letters · 2004 · 73 citations

Combined Doxorubicin, Pharmacological Study, Medicine +4

Induction of the Unfolded Protein Response Drives Enhanced Metabolism and Chemoresistance in Glioma Cells

Laura M. Epple, Rebecca D. Dodd, Andrea L. Merz et al. · PLoS ONE · 2013 · 72 citations · Full text

Metabolic Remodeling, Enhanced Metabolism, Cancer Biology +20

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

Daniel L. Gustafson, Barbara Frederick, Andrea L. Merz et al. · Cancer Chemotherapy and Pharmacology · 2007 · 46 citations

Dose Scheduling, Oncology, Radiation Therapy +8

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson et al. · Clinical Cancer Research · 2007 · 42 citations

Thyroid hormone responsive protein Spot14 enhances catalysis of fatty acid synthase in lactating mammary epithelium

Michael C. Rudolph, Elizabeth A. Wellberg, Andrew Lewis et al. · Journal of Lipid Research · 2014 · 42 citations · Full text

Mammary Epithelium, Fatty Acid Synthase, Lactation +17